MA38194A1 - Anticorps anti-ceacam5 et leurs utilisations - Google Patents

Anticorps anti-ceacam5 et leurs utilisations

Info

Publication number
MA38194A1
MA38194A1 MA38194A MA38194A MA38194A1 MA 38194 A1 MA38194 A1 MA 38194A1 MA 38194 A MA38194 A MA 38194A MA 38194 A MA38194 A MA 38194A MA 38194 A1 MA38194 A1 MA 38194A1
Authority
MA
Morocco
Prior art keywords
antibodies
immunoconjugates
ceacam5 antibodies
conjugated
vectors
Prior art date
Application number
MA38194A
Other languages
English (en)
Other versions
MA38194B1 (fr
Inventor
Pierre-Francois Berne
Francis Blanche
Hervé Bouchard
Béatrice Cameron
Tarik Dabdoubi
Stéphanie Decary
Paul Ferrari
Alexey Rak
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA38194A1 publication Critical patent/MA38194A1/fr
Publication of MA38194B1 publication Critical patent/MA38194B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des anticorps qui se lient à des protéines ceacam5 humaines et de macaca fascicularis ainsi que des acides nucléiques isolés, des vecteurs et des cellules hôtes comprenant une séquence codant pour les anticorps. L'invention concerne également des immunoconjugués comprenant les anticorps conjugués ou liés à un agent d'inhibition de croissance, et des compositions pharmaceutiques comprenant des anticorps ou des immunoconjugués. Les anticorps ou les immunoconjugués de l'invention sont utilisés pour traiter le cancer ou à des fins de diagnostic.
MA38194A 2012-11-20 2013-11-20 Anticorps anti-ceacam5 et leurs utilisations MA38194B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306444 2012-11-20
PCT/EP2013/074291 WO2014079886A1 (fr) 2012-11-20 2013-11-20 Anticorps anti-ceacam5 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA38194A1 true MA38194A1 (fr) 2018-02-28
MA38194B1 MA38194B1 (fr) 2018-12-31

Family

ID=47257727

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38194A MA38194B1 (fr) 2012-11-20 2013-11-20 Anticorps anti-ceacam5 et leurs utilisations

Country Status (38)

Country Link
US (4) US9617345B2 (fr)
EP (3) EP3199552B1 (fr)
JP (1) JP6324399B2 (fr)
KR (4) KR102661801B1 (fr)
CN (2) CN104918958B (fr)
AR (1) AR093557A1 (fr)
AU (2) AU2013349733C1 (fr)
BR (1) BR112015010993B1 (fr)
CA (2) CA2889962C (fr)
CL (1) CL2015001321A1 (fr)
CR (1) CR20150258A (fr)
CY (1) CY1119219T1 (fr)
DK (2) DK2922875T3 (fr)
DO (1) DOP2015000110A (fr)
EA (1) EA039377B1 (fr)
EC (1) ECSP15025845A (fr)
ES (2) ES2625742T3 (fr)
HR (2) HRP20170743T1 (fr)
HU (1) HUE033369T2 (fr)
IL (1) IL238559B (fr)
LT (2) LT2922875T (fr)
MA (1) MA38194B1 (fr)
MX (1) MX358321B (fr)
MY (1) MY171100A (fr)
NZ (1) NZ708528A (fr)
PE (1) PE20151180A1 (fr)
PH (1) PH12015501092B1 (fr)
PL (2) PL3199552T3 (fr)
PT (2) PT2922875T (fr)
RS (2) RS60043B1 (fr)
SG (1) SG11201503285TA (fr)
SI (2) SI2922875T1 (fr)
TN (1) TN2015000177A1 (fr)
TW (2) TWI664192B (fr)
UA (1) UA120247C2 (fr)
UY (1) UY35147A (fr)
WO (1) WO2014079886A1 (fr)
ZA (1) ZA201502959B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
SI2922875T1 (sl) 2012-11-20 2017-06-30 Sanofi Protitelesa anti-CEACAM5 in njihove uporabe
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
SG11201701328XA (en) * 2014-09-02 2017-03-30 Immunogen Inc Methods for formulating antibody drug conjugate compositions
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
WO2018070936A1 (fr) * 2016-10-10 2018-04-19 Singhealth Services Pte Ltd Anticorps anti-ceacam6 et leurs procédés d'utilisation
SG10201912529SA (en) 2016-11-18 2020-02-27 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
CN106946989B (zh) * 2017-03-02 2020-02-18 深圳市国创纳米抗体技术有限公司 抗cea抗原vhh结构域及含有其的双特异性抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CA3069363A1 (fr) * 2017-07-11 2019-01-17 Pfizer Inc. Compositions immunogenes comprenant cea muc1 et tert
EP3502140A1 (fr) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Thérapie de combinaison d'agonistes d'icos ciblés contre la tumeur avec des molécules bispécifiques à cellules t
IL277049B2 (en) 2018-03-13 2024-02-01 Zymeworks Bc Inc Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
WO2019195770A1 (fr) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions et procédés comprenant des anticorps anti-nrp2
US20210236548A1 (en) * 2018-04-20 2021-08-05 The Regents Of The University Of California Treatment of prostate cancer using chimeric antigen receptors
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
JP7403479B2 (ja) 2018-06-03 2023-12-22 ランカプ バイオ ベータ リミテッド Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
KR20250160211A (ko) 2018-08-30 2025-11-11 이뮤니티바이오, 인크. 다중-사슬 키메라 폴리펩타이드 및 이의 용도
CN113365663B (zh) 2018-08-30 2025-11-21 免疫生物公司 单链嵌合多肽和其用途
WO2020047473A1 (fr) 2018-08-30 2020-03-05 HCW Biologics, Inc. Polypeptides chimères à chaîne unique et à chaînes multiples et leurs utilisations
EP3865154A4 (fr) 2018-10-10 2022-11-09 Astellas Pharma Inc. Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
EP3693023A1 (fr) 2019-02-11 2020-08-12 Sanofi Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
MX2021009514A (es) * 2019-02-07 2021-11-04 Sanofi Sa Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
CN114286690A (zh) * 2019-04-23 2022-04-05 赛诺菲 稳定的低粘度抗体配制品及其用途
TW202100560A (zh) * 2019-06-04 2021-01-01 大陸商上海吉倍生物技術有限公司 一種抗ceacam5 的單殖株抗體及其製備方法和用途
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CA3142887A1 (fr) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Composes d'aminobenzazepine, immunoconjugues et leurs utilisations
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3990492A1 (fr) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Nouveaux anticorps anti-icos et molécules de liaison à un antigène ciblant les tumeurs les comprenant
WO2021046112A1 (fr) 2019-09-03 2021-03-11 Bolt Biotherapeutics, Inc. Composés aminoquinoline, immunoconjugués et leurs utilisations
BR112022004995A2 (pt) 2019-09-18 2022-06-21 Lamkap Bio Alpha AG Anticorpos biespecíficos contra ceacam5 e cd3
WO2021067242A1 (fr) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Immunoconjugués d'aminobenzazépine liés à des amides et leurs utilisations
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
TWI857167B (zh) 2019-10-25 2024-10-01 美商博特生物治療公司 噻吩并氮呯免疫結合物及其用途
EP3831849A1 (fr) 2019-12-02 2021-06-09 LamKap Bio beta AG Anticorps bispécifiques contre ceacam5 et cd47
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
CA3169243A1 (fr) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methodes d'activation de lymphocytes t regulateurs
JP2023513573A (ja) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢性および炎症性疾患を治療する方法
MX2022013406A (es) 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
KR20230005257A (ko) 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 folfiri를 함유하는 항종양 병용물
WO2021214223A1 (fr) 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfox
MX2022013404A (es) * 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo.
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
CA3176626A1 (fr) 2020-05-08 2021-11-11 David Dornan Substrat pour elastase, immunoconjugues de liaison peptidique et leurs utilisations
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247604A1 (fr) 2020-06-01 2021-12-09 HCW Biologics, Inc. Méthodes de traitement de troubles liés au vieillissement
WO2021247003A1 (fr) 2020-06-01 2021-12-09 HCW Biologics, Inc. Méthodes de traitement de troubles liés au vieillissement
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
CN112028997B (zh) * 2020-08-04 2021-08-13 中山大学附属第五医院 抗ceacam5纳米抗体
US20230263903A1 (en) 2020-08-13 2023-08-24 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
EP4097486A4 (fr) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. Compositions et méthodes de traitement de cancers positifs à ceacam
EP4100028A4 (fr) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. Compositions et méthodes de traitement de cancers positifs à la mésothéline
KR20230062600A (ko) * 2020-09-04 2023-05-09 메르크 파텐트 게엠베하 항-ceacam5 항체 및 접합체 및 이의 용도
IL302731A (en) * 2020-11-10 2023-07-01 Sanofi Sa Formulation of an antibody-drug conjugate for CEACAM5
WO2022116079A1 (fr) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 Anticorps anti-ceacam5 humanisé et son procédé de préparation et son utilisation
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
CA3200051A1 (fr) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Immunoconjugues anti-cea et leurs utilisations
CA3202255A1 (fr) 2020-12-21 2022-06-30 Hayley WARSINSKE Marqueurs pour la detection precoce de troubles proliferatifs de cellules du colon
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
AU2022233150A1 (en) * 2021-03-08 2023-09-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MOLECULES THAT BIND TO CD66e POLYPEPTIDES
IL306114A (en) 2021-03-26 2023-11-01 Bolt Biotherapeutics Inc 2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof
JP2024511088A (ja) 2021-03-26 2024-03-12 ボルト バイオセラピューティクス、インコーポレーテッド ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用
JP2024519078A (ja) * 2021-05-21 2024-05-08 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｅａ抗体及びその使用方法
IL308660A (en) * 2021-05-21 2024-01-01 Beigene Switzerland Gmbh Multispecific antibodies directed against CEA and against 137CD and methods of using them
KR20240082398A (ko) 2021-10-07 2024-06-10 사노피 이미다조[4,5-c]퀴놀린-4-아민 화합물 및 이의 접합체, 이들의 제조 및 이들의 치료 응용
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
CA3236417A1 (fr) * 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Anticorps monoclonaux contre des antigenes carcinoembryonnaires et leurs utilisations
KR20240112348A (ko) 2021-12-02 2024-07-18 사노피 암 치료법에서 환자 선택을 위한 cea 검정
CA3241254A1 (fr) 2021-12-02 2023-06-08 Sanofi Polytherapie a base de ceacam5 adc anti-pd-1/pd-l1
US20250188170A1 (en) * 2022-02-25 2025-06-12 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES
EP4486368A1 (fr) 2022-03-02 2025-01-08 ImmunityBio, Inc. Méthode de traitement du cancer du pancréas
EP4489861A1 (fr) * 2022-03-09 2025-01-15 Merck Patent GmbH Procédés et outils de conjugaison à des anticorps
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
PE20250928A1 (es) 2022-08-10 2025-04-02 Merck Sharp And Dohme Llc Proteinas de union a nkg2d, cd16 y ceacam5
US20260028415A1 (en) * 2022-12-28 2026-01-29 Full-Life Technologies Hk Limited Antibodies specifically binding to ceacam5
EP4673181A1 (fr) 2023-03-01 2026-01-07 Sanofi Utilisation d'immunoconjugués anti-ceacam5 pour le traitement de cancers neuroendocriniens exprimant ceacam5
EP4427763A1 (fr) 2023-03-06 2024-09-11 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
CN117545780B (zh) * 2023-05-16 2025-12-30 成都优洛生物科技有限公司 抗lilrb1纳米抗体或其抗原结合片段、制备方法和用途
CN121443320A (zh) 2023-06-05 2026-01-30 赛诺菲 含有抗ceacam5抗体-药物缀合物、抗pd1/pd-l1抗体和抗ctla4抗体的抗肿瘤组合
WO2024250924A1 (fr) * 2023-06-05 2024-12-12 Nona Biosciences (Suzhou) Co., Ltd. Anticorps double liaison anti-ceacam5/6
AU2024320501A1 (en) 2023-08-04 2026-03-12 Sanofi Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
WO2025098480A1 (fr) * 2023-11-10 2025-05-15 信达生物制药(苏州)有限公司 Anticorps bispécifique dirigé contre dr5 et ceacam5 et son utilisation
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
WO2025169012A1 (fr) 2024-02-06 2025-08-14 Sanofi Méthodes de traitement de cancers exprimant ceacam5
WO2025184208A1 (fr) * 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anticorps anti-ceacam5 et leurs utilisations
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025242098A1 (fr) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 Conjugué anticorps-médicament ciblant ceacam5 et son utilisation
WO2026002995A1 (fr) 2024-06-24 2026-01-02 Avacta Life Sciences Limited Conjugués inhibiteurs de topoisomérase activés par fap spécifiques à une cible et leurs utilisations
WO2026006689A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués anticorps-dégradeur de bcl-xl et leurs utilisations
WO2026019161A1 (fr) * 2024-07-19 2026-01-22 주식회사 다안바이오테라퓨틱스 Nouvel anticorps anti-ceacam5 et utilisation associée comme agent thérapeutique
US20260049118A1 (en) 2024-08-19 2026-02-19 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2026043906A1 (fr) 2024-08-19 2026-02-26 HCW Biologics, Inc. Polypeptides chimériques à chaînes multiples et leurs utilisations

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US144A (en) 1837-03-11 Improvement in scythe-snaths
US689A (en) 1838-04-13 Julius austin
US4670A (en) 1846-07-28 Improvement in fish-hooks
US244A (en) 1837-06-30 Edward flint
US4640A (en) 1846-07-14 Book-lock
US5204A (en) 1847-07-24 james cantelo
US4496A (en) 1846-05-02 Machinery for
US835A (en) 1838-07-12 X i i i x
US4301A (en) 1845-12-11 Ebenezbr barrows
US417A (en) 1837-09-28 Endless-ghain horse-power for driving iviaci-iii
US4791A (en) 1846-10-03 john g
US192A (en) 1837-05-15 Machine for cutting
US1045773A (en) 1911-08-30 1912-11-26 John A Cole Quick-action electric switch.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
EP0272253A4 (fr) 1986-03-07 1990-02-05 Massachusetts Inst Technology Procede pour ameliorer la stabilite des glycoproteines.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1005870B1 (fr) 1992-11-13 2009-01-21 Biogen Idec Inc. Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
CA2156725A1 (fr) 1993-02-22 1994-09-01 Warren S. Pear Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1997010354A1 (fr) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU7071598A (en) 1997-04-10 1998-10-30 Erasmus University Rotterdam Diagnosis method and reagents
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
WO2007071422A2 (fr) 2005-12-21 2007-06-28 Micromet Ag Compositions d'anticorps pharmaceutique ayant une resistance a cea soluble
WO2007071426A1 (fr) 2005-12-21 2007-06-28 Micromet Ag Préparations pharmaceutiques résistantes à l’ace soluble
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
RU2607569C2 (ru) 2008-03-31 2017-01-10 Дженентек, Инк. Композиции и способы для лечения и диагностики астмы
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
SG10201401976YA (en) 2009-05-06 2014-10-30 Biotest Ag Uses of immunoconjugates targeting cd138
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
EP2478110B1 (fr) * 2009-09-16 2016-01-06 Immunomedics, Inc. Anticorps anti-cea de classe i et leurs utilisations
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
BR112013021460B1 (pt) * 2011-03-02 2022-12-20 Roche Glycart Ag Anticorpos, composição e uso do anticorpo
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
GB2534478A (en) 2012-06-27 2016-07-27 Hasumi Int Res Found Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
SI2922875T1 (sl) 2012-11-20 2017-06-30 Sanofi Protitelesa anti-CEACAM5 in njihove uporabe
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
WO2015069430A2 (fr) 2013-11-05 2015-05-14 Immunomedics, Inc. Anticorps anti-ceacam5 humanisé et ses utilisations
MX377841B (es) 2013-11-21 2025-03-11 Genmab As Formulación liofilizada de conjugado de anticuerpo-fármaco.
MX375221B (es) 2013-11-25 2025-03-06 Famewave Ltd Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
WO2015168607A2 (fr) 2014-05-02 2015-11-05 Icahn School Of Medicine At Mount Sinai Peptides ceacam5 pour la maladie de crohn
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016180941A1 (fr) 2015-05-13 2016-11-17 Sanofi Compositions liquides pour conjugués médicament-anticorps anti-cd19
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
CN104948958A (zh) * 2015-07-01 2015-09-30 上海顿格电子贸易有限公司 一种利用热敏电阻限流的led灯
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
US20200069799A1 (en) 2018-08-28 2020-03-05 Arecor Limited Stabilized antibody protein solutions
EP3606922A4 (fr) 2017-04-06 2021-03-03 Hangzhou Dac Biotech Co., Ltd Conjugaison d'un médicament cytotoxique avec une bis-liaison
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060695A1 (fr) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-recepteur de mort programmee 1 (pd-1) et leurs procedes d'utilisation
WO2018227023A1 (fr) 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Conjugués de construction d'anticorps
US20210261649A1 (en) * 2018-06-29 2021-08-26 Krystal Biotech, Inc, Compositions and methods for antibody delivery
WO2020053301A1 (fr) 2018-09-11 2020-03-19 Ichnos Sciences S.A. Compositions comprenant un anticorps bispécifique, un tampon et un ou plusieurs agents stabilisants
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
WO2020079209A1 (fr) 2018-10-19 2020-04-23 Merck Patent Gmbh Abituzumab pour le traitement du cancer colorectal
MX2021009514A (es) * 2019-02-07 2021-11-04 Sanofi Sa Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
EP3693023A1 (fr) 2019-02-11 2020-08-12 Sanofi Utilisation d'immuno-conjugués anti-ceacam5 pour le traitement du cancer du poumon
US20220152215A1 (en) 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
CA3130794A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugues ciblant le her2
US20220226491A1 (en) 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1
WO2020190731A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
US20220143012A1 (en) 2019-03-15 2022-05-12 Bolt Biotherapeutics, Inc. Macromolecule-Supported TLR Agonists
WO2021067403A1 (fr) 2019-10-01 2021-04-08 Immunomedics, Inc. Biomarqueurs pour une monothérapie ou une polythérapie par un conjugué anticorps-médicament
WO2021214223A1 (fr) 2020-04-24 2021-10-28 Sanofi Combinaisons antitumorales contenant des conjugués d'anticorps anti-ceacam5 et du folfox
MX2022013406A (es) * 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
MX2022013404A (es) * 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5, trifluridina y tipirazilo.
KR20230005257A (ko) * 2020-04-24 2023-01-09 사노피 항-ceacam5 항체 접합체 및 folfiri를 함유하는 항종양 병용물
IL302731A (en) * 2020-11-10 2023-07-01 Sanofi Sa Formulation of an antibody-drug conjugate for CEACAM5
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
KR20240112348A (ko) * 2021-12-02 2024-07-18 사노피 암 치료법에서 환자 선택을 위한 cea 검정
CA3241254A1 (fr) 2021-12-02 2023-06-08 Sanofi Polytherapie a base de ceacam5 adc anti-pd-1/pd-l1
EP4619045A1 (fr) * 2022-11-17 2025-09-24 Sanofi Conjugués anticorps-médicaments de ceacam5 et leurs méthodes d'utilisation
EP4673181A1 (fr) 2023-03-01 2026-01-07 Sanofi Utilisation d'immunoconjugués anti-ceacam5 pour le traitement de cancers neuroendocriniens exprimant ceacam5
EP4427763A1 (fr) 2023-03-06 2024-09-11 Sanofi Combinaisons antitumorales contenant des conjugués anticorps anti-ceacam5-médicament, anticorps anti-vegfr-2 et anticorps anti-pd1/pd-l1
CN120917154A (zh) 2023-03-23 2025-11-07 赛诺菲 用于癌症疗法中的患者选择的CEACAM5 mRNA测定
CN121443320A (zh) 2023-06-05 2026-01-30 赛诺菲 含有抗ceacam5抗体-药物缀合物、抗pd1/pd-l1抗体和抗ctla4抗体的抗肿瘤组合
WO2025169012A1 (fr) 2024-02-06 2025-08-14 Sanofi Méthodes de traitement de cancers exprimant ceacam5

Also Published As

Publication number Publication date
MX2015006374A (es) 2015-10-09
PL3199552T3 (pl) 2020-06-01
ZA201502959B (en) 2016-01-27
EA201590986A1 (ru) 2016-05-31
ES2625742T3 (es) 2017-07-20
ES2778823T3 (es) 2020-08-12
IL238559A0 (en) 2015-06-30
SG11201503285TA (en) 2015-05-28
UY35147A (es) 2014-06-30
CN109180815B (zh) 2022-06-21
AU2013349733B2 (en) 2018-08-23
HK1215444A1 (en) 2016-08-26
CN104918958A (zh) 2015-09-16
DK2922875T3 (en) 2017-06-06
US20160108131A1 (en) 2016-04-21
CY1119219T1 (el) 2018-02-14
HRP20200415T1 (hr) 2020-06-26
KR102661801B1 (ko) 2024-04-26
KR102194748B1 (ko) 2020-12-23
LT2922875T (lt) 2017-06-12
US10457739B2 (en) 2019-10-29
KR20220084193A (ko) 2022-06-21
BR112015010993B1 (pt) 2022-08-30
WO2014079886A1 (fr) 2014-05-30
EA039377B1 (ru) 2022-01-20
US9617345B2 (en) 2017-04-11
DOP2015000110A (es) 2015-08-16
KR102408660B1 (ko) 2022-06-15
US20200102401A1 (en) 2020-04-02
EP3199552A1 (fr) 2017-08-02
CN104918958B (zh) 2019-12-10
CL2015001321A1 (es) 2015-07-17
SI2922875T1 (sl) 2017-06-30
ECSP15025845A (es) 2016-01-29
NZ708528A (en) 2020-07-31
EP2922875A1 (fr) 2015-09-30
IL238559B (en) 2018-10-31
US11332542B2 (en) 2022-05-17
EP3199552B1 (fr) 2019-12-25
CA3207769A1 (fr) 2014-05-30
BR112015010993A2 (fr) 2017-08-22
TN2015000177A1 (en) 2016-10-03
PT3199552T (pt) 2020-03-25
US20180022817A1 (en) 2018-01-25
KR20200143527A (ko) 2020-12-23
PH12015501092A1 (en) 2015-07-27
AU2013349733A1 (en) 2015-06-11
AR093557A1 (es) 2015-06-10
TW201427997A (zh) 2014-07-16
SI3199552T1 (sl) 2020-06-30
JP6324399B2 (ja) 2018-05-16
HUE033369T2 (en) 2017-11-28
JP2016506370A (ja) 2016-03-03
RS55987B1 (sr) 2017-09-29
CR20150258A (es) 2015-06-11
EP2922875B1 (fr) 2017-03-15
CA2889962A1 (fr) 2014-05-30
PE20151180A1 (es) 2015-08-12
TW201940519A (zh) 2019-10-16
CA2889962C (fr) 2023-10-24
MA38194B1 (fr) 2018-12-31
PH12015501092B1 (en) 2019-01-11
AU2013349733C1 (en) 2020-10-01
UA120247C2 (uk) 2019-11-11
TWI664192B (zh) 2019-07-01
DK3199552T3 (da) 2020-03-30
CN109180815A (zh) 2019-01-11
HRP20170743T1 (hr) 2017-07-28
KR20240063172A (ko) 2024-05-09
EP3594243A1 (fr) 2020-01-15
AU2018267636A1 (en) 2018-12-13
KR20150085828A (ko) 2015-07-24
RS60043B1 (sr) 2020-04-30
MX358321B (es) 2018-08-14
US20220340682A1 (en) 2022-10-27
LT3199552T (lt) 2020-04-10
MY171100A (en) 2019-09-25
PL2922875T3 (pl) 2017-08-31
PT2922875T (pt) 2017-05-31
US12570761B2 (en) 2026-03-10

Similar Documents

Publication Publication Date Title
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA45280B1 (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA52742B1 (fr) Anticorps bispécifiques dll3-cd3
MA56289A (fr) Mutéines d'interleukine-21 et méthodes de traitement
MA40813A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
EA202090372A1 (ru) Универсальные соединения авт и их применение
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA49158B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA43466A1 (fr) Traitements du cancer de l'utérus
EA201790986A1 (ru) Антитела к cd73 и их применения
MA46022B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA41521A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
MA38986B1 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
MA39378B2 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
MA49155B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA37464A1 (fr) Anticorps anti-egfr et leurs utilisations
MA50737B1 (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
MA38794B1 (fr) Nouvelle immunothérapie contre plusieurs tumeurs, tels que le cancer du poumon, comprenant le cancer du poumon à grandes cellules